O'Laughlen Mary C, Hollen Patricia J, Rance Karen, Rovnyak Virginia, Hinton Ivora, Hellems Martha A, Radecki Linda
J Pediatr Health Care. 2015 Sep-Oct;29(5):402-12. doi: 10.1016/j.pedhc.2015.01.003. Epub 2015 Mar 4.
Although adolescent substance use can have direct effects on asthma symptoms and interact with medications used to treat asthma, no validated health-related quality of life (HRQL) instrument exists for adolescents 17 to 19 years of age with asthma.
The American Academy of Pediatric's HRQL instrument, the Child Health Survey for Asthma (CHSA)-Child version, was modified with a substance use subscale to address outcomes specific to adolescents ages 17 to 19 years with asthma.
Two cohorts (N = 70) were recruited for instrument testing at pediatric primary care practices and two university clinics. A small methodological study with 24 adolescents was conducted to obtain initial support of the psychometric properties for the CHSA-Teen version at baseline, day 14, and day 16. A follow-up study included 46 teens to provide further support.
The psychometric properties of the CHSA-Teen version were good and comparable with the CHSA-Child version for feasibility, reliability, and validity.
Health care providers need to be aware of each adolescent's substance use to personalize counseling related to asthma medications.
尽管青少年使用药物会直接影响哮喘症状,并与用于治疗哮喘的药物相互作用,但目前尚无针对17至19岁哮喘青少年的经过验证的健康相关生活质量(HRQL)工具。
美国儿科学会的HRQL工具——儿童哮喘健康调查(CHSA)儿童版,通过添加一个药物使用分量表进行了修改,以解决17至19岁哮喘青少年的特定结果问题。
在儿科初级保健机构和两家大学诊所招募了两个队列(N = 70)进行工具测试。对24名青少年进行了一项小型方法学研究,以在基线、第14天和第16天获得CHSA青少年版心理测量特性的初步支持。一项随访研究纳入了46名青少年以提供进一步支持。
CHSA青少年版的心理测量特性良好,在可行性、可靠性和有效性方面与CHSA儿童版相当。
医疗保健提供者需要了解每个青少年的药物使用情况,以便针对哮喘药物进行个性化咨询。